Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
1 Experimental Neurosurgery, Center for Neurology and Neurosurgery 2 Department of Anatomy III, Johann Wolfgang Goethe-University Clinics, D-60590 Frankfurt, Germany 3 Department of Physiology, Neuroscience Research Centre, Royal College of Surgeons in Ireland, Dublin 2, Ireland
Correspondence to Jochen H.M. Prehn: prehn{at}rcsi.ie
Abstract:
Transforming growth factor-ßs (TGF-ßs) arepleiotropic cytokines involved in development and maintenanceof the nervous system. In several neural lesion paradigms, TGF-ß1exerts potent neuroprotective effects. Neurons treated withTGF-ß1 activated the canonical TGF-ß receptorI/activin-like kinase receptor 5 (ALK5) pathway. The transcriptionfactor nuclear factor-B (NF-B) plays a fundamental role in neuroprotection.Treatment with TGF-ß1 enhanced NF-B activity in gelshiftand reporter gene analyses. However, ectopic expression of aconstitutively active ALK5 failed to mimic these effects. ALK1has been described as an alternative TGF-ß receptorin endothelial cells. Interestingly, we detected significantbasal expression of ALK1 and its injury-induced up-regulationin neurons. Treatment with TGF-ß1 also induced a pronouncedincrease in downstream Smad1 phosphorylation. Overexpressionof a constitutively active ALK1 mimicked the effect of TGF-ß1on NF-B activation and neuroprotection. Our data suggest thatTGF-ß1 simultaneously activates two distinct receptorpathways in neurons and that the ALK1 pathway mediates TGF-ß1inducedNF-B survival signaling.
Abbreviations used in this paper: ALK5, activin-like kinase5; BMP, bone morphogenetic protein; DIV, days in vitro; GFAP,glial acidic fibrillary protein; MCAO, middle cerebral arteryocclusion; NF-B, nuclear factor-B; NMDA, N-methyl-D-aspartate;NO, nitric oxide; PI, propidium iodide; SNOC, S-nitroso-cysteine;TßRI, TGF-ß receptor type I; TGF-ß,transforming growth factor-ß.
The editors suggest the following Related Resources on Science sites:
TGF{beta} Signaling Induces Expression of Gadd45b in Retinal Ganglion Cells.
B. Liu, X. Sun, G. Suyeoka, J. G. N. Garcia, and Y. I. Leiderman (2013)
Invest. Ophthalmol. Vis. Sci.
54, 1061-1069
|Abstract »|Full Text »|PDF »
New findings in osteoarthritis pathogenesis: therapeutic implications.
L. Pulsatelli, O. Addimanda, V. Brusi, B. Pavloska, and R. Meliconi (2013)
Therapeutic Advances in Chronic Disease
4, 23-43
|Abstract »|PDF »
Fibroblast growth factor homologous factor 1 interacts with NEMO to regulate NF-{kappa}B signaling in neurons.
H.-G. Konig, B. J. Fenner, J. C. Byrne, R. F. Schwamborn, T. Bernas, C. A. Jefferies, and J. H. M. Prehn (2012)
J. Cell Sci.
125, 6058-6070
|Abstract »|Full Text »|PDF »
Y. Tang, S. Urs, J. Boucher, T. Bernaiche, D. Venkatesh, D. B. Spicer, C. P. H. Vary, and L. Liaw (2010)
J. Biol. Chem.
285, 17556-17563
|Abstract »|Full Text »|PDF »
Canonical TGF-{beta} Signaling Is Required for the Balance of Excitatory/Inhibitory Transmission within the Hippocampus and Prepulse Inhibition of Acoustic Startle.
M. Sun, J. C. Gewirtz, L. Bofenkamp, R. J. Wickham, H. Ge, and M. B. O'Connor (2010)
J. Neurosci.
30, 6025-6035
|Abstract »|Full Text »|PDF »
The type III transforming growth factor-{beta} receptor negatively regulates nuclear factor kappa B signaling through its interaction with {beta}-arrestin2.
Intracisternal administration of transforming growth factor- evokes fever through the induction of cyclooxygenase-2 in brain endothelial cells.
S. Matsumura, T. Shibakusa, T. Fujikawa, H. Yamada, K. Matsumura, K. Inoue, and T. Fushiki (2008)
Am J Physiol Regulatory Integrative Comp Physiol
294, R266-R275
|Abstract »|Full Text »|PDF »
Microarray Analysis of the Cellular Pathways Involved in the Adaptation to and Progression of Motor Neuron Injury in the SOD1 G93A Mouse Model of Familial ALS.
L. Ferraiuolo, P. R. Heath, H. Holden, P. Kasher, J. Kirby, and P. J. Shaw (2007)
J. Neurosci.
27, 9201-9219
|Abstract »|Full Text »|PDF »
Dose-dependent cross-talk between the transforming growth factor-{beta} and interleukin-1 signaling pathways.
T. Lu, L. Tian, Y. Han, M. Vogelbaum, and G. R. Stark (2007)
PNAS
104, 4365-4370
|Abstract »|Full Text »|PDF »
Bioluminescence imaging of Smad signaling in living mice shows correlation with excitotoxic neurodegeneration.
J. Luo, A. H. Lin, E. Masliah, and T. Wyss-Coray (2006)
PNAS
103, 18326-18331
|Abstract »|Full Text »|PDF »
Transforming growth factor-beta1 differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells.
W. Qi, X. Chen, J. Holian, E. Mreich, S. Twigg, R. E. Gilbert, and C. A. Pollock (2006)
Am J Physiol Renal Physiol
291, F1070-F1077
|Abstract »|Full Text »|PDF »
Glucocorticoid Receptor and Nuclear Factor-{kappa}B Interactions in Restraint Stress-Mediated Protection against Acoustic Trauma.
Y. Tahera, I. Meltser, P. Johansson, A. C. Hansson, and B. Canlon (2006)
Endocrinology
147, 4430-4437
|Abstract »|Full Text »|PDF »
Role of transforming growth factor-beta in hematologic malignancies.